Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Carcinoma

Breast Neoplasms

Breast Carcinoma In Situ

Carcinoma in Situ

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Breast Diseases

Skin Diseases

Hypoglycemic Agents

All Drugs and Chemicals

Other Dietary Supplements

Metformin

Biguanides

Omega 3 Fatty Acid

Open Label- Metformin and Omega-3 fatty acids for 12 months post baseline data collection.

Metformin 850mg, oral, twice a day for 12 months

Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months

Omega-3 fatty acids

Katherine Crew, MD, MS

The purpose of this study is to determine whether it is feasible to give a combination of Metformin and omega-3 fatty acids for one year to women with a history of early stage breast cancer. We will also evaluate whether the metformin and omega-3 fatty acids combination causes changes in breast tissue, blood, and mammograms.

Metformin is a medication used to treat and prevent diabetes and omega-3 fatty acids has been shown to lower cholesterol and improve cardiovascular health. Research has shown that Metformin and omega-3 fatty acids may also be effective in preventing cancer. In this study, we want to find out what effects, good and/or bad, the Metformin and omega-3 fatty acids combination has on you and your risk of developing a new breast cancer.

Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer

Pilot Biomarker Modulation Study of Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer

The primary objective is to assess the safety and feasibility of a one-year intervention of metformin and omega-3 fatty acids in early stage breast cancer patients who completed adjuvant treatment.

Determine the efficacy of these drug interventions in reducing mammographic density

Determine the efficacy of these drug interventions in modulating markers of insulin signaling.

Determine the efficacy of these drug interventions in modulating metabolic profile markers.

Determine the efficacy of these drug interventions in modulating inflammatory markers.

Determine the efficacy of these drug interventions in modulating anthropometric measures.

Katherine D. Crew

Assistant Professor of Medicine and Epidemiology

radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery

radioguided seed localization for nonpalpable breast cancers

Peter J Lovrics, MD

Mary Townsend

The purpose of this study is to determine whether a new surgical technique (radioguided seed localization) for localizing nonpalpable breast tumours is better than the standard technique (needle localization).

Most breast cancers are removed by partial mastectomy/lumpectomy. The most important factor in ensuring that the cancer does not return in the breast is to ensure that it is completely removed during surgery. Complete removal is dependent on having a rim of normal tissue (clear margin) surrounding the cancer. If the margin is positive, or the cancer recurs, more surgery or mastectomy is required. Approximately one third of breast cancers are detected by mammograms or ultrasounds and cannot be felt by patients or physicians. Accordingly, a localization technique is required to help the surgeon to find and remove the cancer. The current technique (needle localization) has a higher chance of having cancer cells at the margin. This is a study about a surgical technique. The objective of this comparison study is to determine whether a new technique (radioguided seed localization) is a better way to remove nonpalpable breast cancers. The main objective of this study is to determine if the new technique generates fewer positive margins compared to the standard technique. An improved technique would benefit thousands of women every year.

Trial Comparing Radioactive Seed Localization to Standard Procedure for Non-palpable Breast Cancers

A Prospective, Randomized, Controlled Trial of Radioguided Seed Localization Versus Standard Needle Localization of Nonpalpable Breast Cancers

Canadian Breast Cancer Foundation

McMaster University

Dr. Peter J. Lovrics

Carcinoma, Lobular

Adenocarcinoma

Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure.

Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.

Intraoperative Radiotherapy

Lawrence Wagman, M.D.

This clinical trial is being conducted to find out the effects (good and bad) of giving the full radiation treatment for breast cancer as a single dose of radiation during surgery for breast cancer. This single fraction intraoperative radiotherapy with electrons will study the toxicity, local control and cosmetic outcome.

For patients with certain types of breast cancer, one standard treatment is breast conserving surgery or lumpectomy (surgery to remove abnormal tissue or cancer from the breast and a small amount of normal tissue around it) followed by breast radiation. The radiation treatment in this situation usually lasts 3 to 5 1/2 weeks followed by 5-8 daily localized irradiation (or boost) treatments at the site where the lump was removed. During this study, the single dose of electron irradiation given at the surgical site during the operation will replace the radiation given after surgery.

Single Fraction Intraoperative Radiotherapy

Single Fraction Intraoperative Radiotherapy With Electrons: An Option in Breast-Conserving Operable Breast Cancer Stages 0, I and II - Prospective, Single-arm Trial

Assessment of acute toxicity of breast irradiation according to CTC-toxicity Scoring - system:

* End of initial surgical phase: Week 1, 4
* First Follow-up investigation: Month 2 Assessment of late toxicity according to NSABP scoring-systems at 6, 12, 24, 36, 48, and 60 months

Assessment of cosmetic outcome according to 5-point scoring system

* Week 1, 2; Month 2, 6, 12, 24, 36, 48, 60
* At yearly follow-up (photodocumentation in standardized positions) for 5 years

Recurrence is assessed at month 6, 12, 24, 36, 48, 60

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer	NCT02278965	Stage 0 Breast ... Breast Neoplasm... Stage I Breast ... Stage II Breast... Stage III Breas...	Metformin Omega-3 fatty a...	21 Years - 75 Years	Columbia University
Trial Comparing Radioactive Seed Localization to Standard Procedure for Non-palpable Breast Cancers	NCT00225927	Breast Cancer I... Stage 0 Breast ...	radioguided see...	18 Years -	McMaster University
Single Fraction Intraoperative Radiotherapy	NCT01688388	Invasive Ductal... Stage 0 Breast ... Stage I Breast ... Stage II Breast...	Intraoperative ...	41 Years - 90 Years	St. Joseph Hospital of Orange

Spots Global Cancer Trial Database for stage 0 breast carcinoma